Insider filing · DMAC

Jan Stahlberg bought $5.9M of DiaMedica Therapeutics (DMAC)

Executed Aug 13 2025, disclosed Sep 4 2025, 22 days later, against a two-business-day limit.

Over the 21 trading sessions from the disclosed entry session (Sep 4 2025), the stock returned +32.3% (delay-adjusted); from the execution session (Aug 13 2025), +48.6%. Derived: entry at the session's open, exit at the close 20 sessions later.

JS Jan Stahlberg 10% owner profile →

Jan Stahlberg (10% owner) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales, 1 filed past the two-business-day deadline), most often in DMAC. Across 1 priced purchase filing, the average 21-session return was +48.7% from execution and -5.1% from disclosure (delay-adjusted; derived). The largest single filing was $7.6M of DMAC (1,061,277 sh across 7 lots, as filed), executed Nov 17 2025.

DMAC DMAC DMAC · 5 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→